BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 114.13 USD 0.55% Market Closed
Market Cap: 27.5B USD
Have any thoughts about
BioNTech SE?
Write Note

BioNTech SE
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioNTech SE
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
BioNTech SE
NASDAQ:BNTX
Total Receivables
€2.3B
CAGR 3-Years
139%
CAGR 5-Years
142%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Receivables
€30.8m
CAGR 3-Years
-33%
CAGR 5-Years
8%
CAGR 10-Years
-12%
CureVac NV
NASDAQ:CVAC
Total Receivables
€23m
CAGR 3-Years
79%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Total Receivables
€5.7m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Receivables
€171.8m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Total Receivables
€28.3m
CAGR 3-Years
54%
CAGR 5-Years
41%
CAGR 10-Years
N/A
No Stocks Found

BioNTech SE
Glance View

Market Cap
27.4B USD
Industry
Biotechnology

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
32.68 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

What is BioNTech SE's Total Receivables?
Total Receivables
2.3B EUR

Based on the financial report for Dec 31, 2023, BioNTech SE's Total Receivables amounts to 2.3B EUR.

What is BioNTech SE's Total Receivables growth rate?
Total Receivables CAGR 5Y
142%

Over the last year, the Total Receivables growth was -67%. The average annual Total Receivables growth rates for BioNTech SE have been 139% over the past three years , 142% over the past five years .

Back to Top